ロード中...
Workup and Management of Immune‐Mediated Hepatobiliary Pancreatic Toxicities That Develop During Immune Checkpoint Inhibitor Treatment
Immune checkpoint inhibitor treatment has been approved by the U.S. Food and Drug Administration for the treatment of a wide range of cancer types, including hepatocellular carcinoma. Workup and management of immune‐mediated hepatitis, pancreatitis, or cholangitis that develops during immune checkpo...
保存先:
| 出版年: | Oncologist |
|---|---|
| 主要な著者: | , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7011649/ https://ncbi.nlm.nih.gov/pubmed/32043797 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2018-0162 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|